Moncayo Alvaro
Universidad de los Andes, Bogotá, Colombia.
Mem Inst Oswaldo Cruz. 2003 Jul;98(5):577-91. doi: 10.1590/s0074-02762003000500001. Epub 2003 Sep 8.
Chagas disease, named after Carlos Chagas who first described it in 1909, exists only on the American Continent. It is caused by a parasite, Trypanosoma cruzi, transmitted to humans by blood-sucking triatomine bugs and by blood transfusion. Chagas disease has two successive phases, acute and chronic. The acute phase lasts 6 to 8 weeks. After several years of starting the chronic phase, 20% to 35% of the infected individuals, depending on the geographical area will develop irreversible lesions of the autonomous nervous system in the heart, esophagus, colon and the peripheral nervous system. Data on the prevalence and distribution of Chagas disease improved in quality during the 1980's as a result of the demographically representative cross-sectional studies carried out in countries where accurate information was not available. A group of experts met in Bras lia in 1979 and devised standard protocols to carry out countrywide prevalence studies on human T. cruzi infection and triatomine house infestation. Thanks to a coordinated multi-country program in the Southern Cone countries the transmission of Chagas disease by vectors and by blood transfusion has been interrupted in Uruguay in1997, in Chile in 1999, and in 8 of the 12 endemic states of Brazil in 2000 and so the incidence of new infections by T. cruzi in the whole continent has decreased by 70%. Similar control multi-country initiatives have been launched in the Andean countries and in Central America and rapid progress has been recorded to ensure the interruption of the transmission of Chagas disease by 2005 as requested by a Resolution of the World Health Assembly approved in 1998. The cost-benefit analysis of the investments of the vector control program in Brazil indicate that there are savings of US$17 in medical care and disabilities for each dollar spent on prevention, showing that the program is a health investment with good return. Since the inception in 1979 of the Steering Committee on Chagas Disease of the Special Program for Research and Training in Tropical Diseases of the World Health Organization (TDR), the objective was set to promote and finance research aimed at the development of new methods and tools to control this disease. The well known research institutions in Latin America were the key elements of a world wide network of laboratories that received - on a competitive basis - financial support for projects in line with the priorities established. It is presented the time line of the different milestones that were answering successively and logically the outstanding scientific questions identified by the Scientific Working Group in 1978 and that influenced the development and industrial production of practical solutions for diagnosis of the infection and disease control.
恰加斯病以卡洛斯·恰加斯的名字命名,他于1909年首次描述了这种疾病,该病仅存在于美洲大陆。它由一种寄生虫——克氏锥虫引起,通过吸血的锥蝽以及输血传播给人类。恰加斯病有急性和慢性两个连续阶段。急性期持续6至8周。在进入慢性期数年之后,根据地理区域不同,20%至35%的感染者会在心脏、食管、结肠以及外周神经系统出现自主神经系统的不可逆病变。20世纪80年代,由于在缺乏准确信息的国家开展了具有人口统计学代表性的横断面研究,恰加斯病的患病率和分布数据质量得到了改善。1979年,一组专家在巴西利亚会面,制定了在全国范围内开展人体克氏锥虫感染和锥蝽家庭感染患病率研究的标准方案。得益于南锥体国家的一项协调多国计划,恰加斯病通过病媒和输血传播在1997年于乌拉圭被阻断,1999年在智利被阻断,2000年在巴西12个流行州中的8个州被阻断,因此整个大陆克氏锥虫新感染的发病率下降了70%。安第斯国家和中美洲也发起了类似的多国控制举措,并已取得快速进展,以确保按照1998年世界卫生大会批准的一项决议的要求,到2005年阻断恰加斯病的传播。对巴西病媒控制计划投资的成本效益分析表明,每投入1美元用于预防,在医疗护理和残疾方面可节省17美元,这表明该计划是一项回报良好的健康投资。自1979年世界卫生组织热带病研究和培训特别规划署(TDR)恰加斯病指导委员会成立以来,其目标就是促进并资助旨在开发控制该病新方法和新工具的研究。拉丁美洲的知名研究机构是一个全球实验室网络的关键组成部分,这些实验室在竞争基础上获得了符合既定优先事项的项目资金支持。本文展示了不同里程碑事件的时间线,这些事件依次且合乎逻辑地回答了科学工作组在1978年确定的突出科学问题,并影响了用于感染诊断和疾病控制的实际解决方案的开发及工业化生产。